JP5583591B2 - Ｗｉｓｅ結合抗体及びエピトープ - Google Patents

Ｗｉｓｅ結合抗体及びエピトープ Download PDF

Info

Publication number
JP5583591B2
JP5583591B2 JP2010534969A JP2010534969A JP5583591B2 JP 5583591 B2 JP5583591 B2 JP 5583591B2 JP 2010534969 A JP2010534969 A JP 2010534969A JP 2010534969 A JP2010534969 A JP 2010534969A JP 5583591 B2 JP5583591 B2 JP 5583591B2
Authority
JP
Japan
Prior art keywords
seq
wise
antibody
antigen
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010534969A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504501A (ja
JP2011504501A5 (enExample
Inventor
チエン，シユエミン
グラハム，ケビン
シマモト，グラント
チツプトン，バーバラ・エス
ツアイ，メイ−メイ
ウインターズ，アーロン・ジヨージ
チヤン，リー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2011504501A publication Critical patent/JP2011504501A/ja
Publication of JP2011504501A5 publication Critical patent/JP2011504501A5/ja
Application granted granted Critical
Publication of JP5583591B2 publication Critical patent/JP5583591B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2010534969A 2007-11-21 2008-11-21 Ｗｉｓｅ結合抗体及びエピトープ Expired - Fee Related JP5583591B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21
US61/004,037 2007-11-21
PCT/US2008/012987 WO2009070243A2 (en) 2007-11-21 2008-11-21 Wise binding agents and epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014061293A Division JP2014167002A (ja) 2007-11-21 2014-03-25 Ｗｉｓｅ結合抗体及びエピトープ

Publications (3)

Publication Number Publication Date
JP2011504501A JP2011504501A (ja) 2011-02-10
JP2011504501A5 JP2011504501A5 (enExample) 2012-01-12
JP5583591B2 true JP5583591B2 (ja) 2014-09-03

Family

ID=40524859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534969A Expired - Fee Related JP5583591B2 (ja) 2007-11-21 2008-11-21 Ｗｉｓｅ結合抗体及びエピトープ
JP2014061293A Withdrawn JP2014167002A (ja) 2007-11-21 2014-03-25 Ｗｉｓｅ結合抗体及びエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014061293A Withdrawn JP2014167002A (ja) 2007-11-21 2014-03-25 Ｗｉｓｅ結合抗体及びエピトープ

Country Status (17)

Country Link
US (2) US8043620B2 (enExample)
EP (1) EP2220118A2 (enExample)
JP (2) JP5583591B2 (enExample)
KR (1) KR20100099193A (enExample)
CN (1) CN101925611A (enExample)
AU (1) AU2008330125B2 (enExample)
BR (1) BRPI0820387A2 (enExample)
CA (1) CA2705879A1 (enExample)
CO (1) CO6311002A2 (enExample)
CR (1) CR11523A (enExample)
EA (1) EA201000844A1 (enExample)
IL (1) IL205569A0 (enExample)
MA (1) MA31918B1 (enExample)
MX (1) MX2010005656A (enExample)
TN (1) TN2010000213A1 (enExample)
WO (1) WO2009070243A2 (enExample)
ZA (1) ZA201003578B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
RU2016105962A (ru) * 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
EP2542582A4 (en) * 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CA2857645A1 (en) 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
US20130177579A1 (en) * 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
US9549993B2 (en) * 2012-10-02 2017-01-24 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activate matripase
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
CA2922937A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
JP7145374B2 (ja) 2016-03-18 2022-10-03 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
CN114364694B (zh) * 2019-07-12 2024-05-10 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
FI3345607T3 (fi) * 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AR076668A1 (es) * 2009-05-12 2011-06-29 Pfizer Anticuerpos especificos para dkk-1 y sus usos

Also Published As

Publication number Publication date
JP2011504501A (ja) 2011-02-10
WO2009070243A3 (en) 2009-10-29
BRPI0820387A2 (pt) 2015-05-26
CO6311002A2 (es) 2011-08-22
ZA201003578B (en) 2011-04-28
MX2010005656A (es) 2010-11-12
JP2014167002A (ja) 2014-09-11
US20090130114A1 (en) 2009-05-21
US20120003237A1 (en) 2012-01-05
US8043620B2 (en) 2011-10-25
CR11523A (es) 2010-12-16
IL205569A0 (en) 2010-12-30
MA31918B1 (fr) 2010-12-01
WO2009070243A2 (en) 2009-06-04
AU2008330125B2 (en) 2012-11-22
KR20100099193A (ko) 2010-09-10
EA201000844A1 (ru) 2011-10-31
CN101925611A (zh) 2010-12-22
US8309092B2 (en) 2012-11-13
AU2008330125A1 (en) 2009-06-04
CA2705879A1 (en) 2009-06-04
EP2220118A2 (en) 2010-08-25
TN2010000213A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
US8043620B2 (en) Wise binding agents and epitopes
US11542325B2 (en) Anti-activin A antibodies and uses thereof
US20120288507A1 (en) Wise binding agents and epitopes
JP2023065375A (ja) 胸腺間質性リンパ球性新生因子に結合することができる抗原結合タンパク質
TWI494320B (zh) 結合劑
EP2423226A2 (en) Antibody-based diagnostics and therapeutics
EP2460828A2 (en) Antibodies and diagnostics
JP2010502740A5 (enExample)
CN107531795A (zh) Pcsk9抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140326

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140716

R150 Certificate of patent or registration of utility model

Ref document number: 5583591

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees